This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

NBI-56418 second generation

Neurocrine Biosciences, Inc.

Drug Names(s): NBI-56418 second generation

Description: Neurocrine is developing a second generation compound to NBI-56418, which is an orally active, non-peptide GnRH inhibitor as an alternative to injected protein GnRH antagonists.


NBI-56418 second generation News

Pink Sheet Biotech Patents

Pink Sheet cGMP Initiative


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug